Notice of Special Interest (NOSI): Development and Preliminary Testing of Health-related Behavioral Interventions
Notice Number:
NOT-OD-20-106

Key Dates

Release Date:
May 19, 2020
First Available Due Date:
July 23, 2020
Expiration Date:
September 26, 2022

Related Announcements

PAR-19-213 - Behavioral & Integrative Treatment Development Program (R34 Clinical Trial Optional)

PAR-19-212 - Behavioral & Integrative Treatment Development Program (R01 Clinical Trial Optional)

PA-18-849 - Prevention Research in Mid-Life Adults (R01 Clinical Trial Optional)

PA-18-850 - Prevention Research in Mid-Life Adults (R21 Clinical Trial Optional)

PA-18-722 - Improving Patient Adherence to Treatment and Prevention Regimens to Promote Health (R01 Clinical Trial Optional)

PA-18-723 - Improving Patient Adherence to Treatment and Prevention Regimens to Promote Health (R21 Clinical Trial Optional)

PAR-18-581 - Emotional Function in Normal Aging and/or MCI and AD/ADRD (R01 - Clinical Trial Optional)

PAR-18-877 - Early Stage Clinical Trials for the Spectrum of Alzheimer's Disease and Age-related Cognitive Decline (R01 Clinical Trial Optional)

PAR-20-070 - Research Infrastructure Development for Interdisciplinary Aging Studies (R21/R33 - Clinical Trial Optional)

PAR-19-070 - Research on Current Topics in Alzheimer's Disease and Its Related Dementias (R01 Clinical Trial Optional)

PA-20-184- NIH Research Project Grant (Parent R01 Basic Experimental Studies with Humans Required)

PA-20-183 - Research Project Grant (Parent R01 Clinical Trial Required)

PA-20-185 - NIH Research Project Grant (Parent R01 Clinical Trial Not Allowed)

PA-20-196 - NIH Exploratory/Developmental Research Grant Program (Parent R21 Basic Experimental Studies with Humans Required)

PA-20-194 - NIH Exploratory/Developmental Research Grant Program (Parent R21 Clinical Trial Required)

PAR-18-069 - Modular R01s in Cancer Control and Population Sciences (R01 Clinical Trial Optional)

PAR-19-309 - Stimulating Innovations in Behavioral Intervention Research for Cancer Prevention and Control (R21 Clinical Trial Optional)

PAR-18-559 - Cancer Prevention and Control Clinical Trials Grant Program (R01 Clinical Trial Required)

PAR-18-307 - Developing Interventions for Health-Enhancing Physical Activity (R21/R33 - Clinical Trial Optional)

PAR-18-892 - Physical Activity and Weight Control Interventions Among Cancer Survivors: Effects on Biomarkers of Prognosis and Survival (R21 Clinical Trial Optional)

PAR-18-893 - Physical Activity and Weight Control Interventions Among Cancer Survivors: Effects on Biomarkers of Prognosis and Survival (R01 Clinical Trial Optional)

PAR-18-656 - NIDCR Behavioral and Social Intervention Clinical Trial Planning and Implementation Cooperative Agreement (UG3/UH3 Clinical Trial Required)

PA-18-932 - Increasing Uptake of Evidence-Based Screening in Diverse Adult Populations (R01 Clinical Trial Optional)

PAR-18-612 - Electronic Nicotine Delivery Systems (ENDS): Population, Clinical and Applied Prevention Research (R01 Clinical Trial Optional)

PAR-18-611 - Electronic Nicotine Delivery Systems (ENDS): Population, Clinical and Applied Prevention Research (R21 Clinical Trial Optional)

PA-18-729 - Research on the Health of Transgender and Gender Nonconforming Populations (R01 Clinical Trial Optional)

PA-18-728 - Research on the Health of Transgender and Gender Nonconforming Populations (R21 Clinical Trial Optional)

PAR-19-274 - Dissemination and Implementation Research in Health (R01 Clinical Trial Optional)

PAR-19-275 - Dissemination and Implementation Research in Health (R21 Clinical Trial Optional)

PAR-17-491 - Implementing the Most Successful Interventions to Improve HIV/AIDS Outcomes in U.S. Communities (R01 Clinical Trial Optional)

PA-18-849 - Prevention Research in Mid-Life Adults (R01 Clinical Trial Optional)

PA-18-945 - Applying a Biopsychosocial Perspective to Self-Management of Chronic Pain (R01 Clinical Trial Optional)

PA-18-944 - Biobehavioral Basis of Chronic Pain (R01 Clinical Trial Optional)

PA-18-943 - Biobehavioral Basis of Chronic Pain (R21 Clinical Trial Optional)

PAR-19-045 - End-of-Life and Palliative Care Approaches to Advanced Signs and Symptoms (R01 Clinical Trial Optional)

PAR-19-044 - End-of-Life and Palliative Care Approaches to Advanced Signs and Symptoms (R21 Clinical Trial Optional)

PAR-19-057 - Strategies to Provide Culturally Tailored Palliative and End-of-Life Care for Seriously Ill American Indian and Alaska Native Individuals (R01 Clinical Trial Optional)

PAR-19-058 - Strategies to Provide Culturally Tailored Palliative and End-of-Life Care for Seriously Ill American Indian and Alaska Native Individuals (R21 Clinical Trial Optional)

PAR-19-136 - End-of-Life and Palliative Needs of Adolescents and Young Adults (AYA) with Serious Illnesses (R01 Clinical Trial Optional)

PAR-19-153 - End-of-Life and Palliative Needs of Adolescents and Young Adults (AYA) with Serious Illnesses (R21 Clinical Trial Optional)

PAR-19-321- Palliative Care in Home and Community Settings (R01 Clinical Trial Optional)

PAR-19-320 - Palliative Care in Home and Community Settings (R21 Clinical Trial Optional)

PAR-18-595 - Exploratory Clinical Trial Grants in Arthritis and Musculoskeletal and Skin Diseases (R21 Clinical Trial Required)

PA-18-592 - Research Supplements to Promote Re-Entry into Biomedical and Behavioral Research Careers (Admin Supp - Clinical Trial Not Allowed)

RFA-MH-18-704 - Development of Psychosocial Therapeutic and Preventive Interventions for Mental Disorders (R61/R33 - Clinical Trial Required)

RFA-MH-18-705- Development of Psychosocial Therapeutic and Preventive Interventions for Mental Disorders (R33 - Clinical Trial Required)

RFA-MH-18-706 - Pilot Effectiveness Trials for Treatment, Preventive and Services Interventions (R34 - Clinical Trial Required)

PA-20-141 - Formative and Pilot Intervention Research for Prevention and Treatment of HIV/AIDS (R34 - Clinical Trial Optional)

PA-18-322 - Fundamental Science Research on Mind and Body Approaches (R21 Clinical Trial Optional)

PA-18-323 - Fundamental Science Research on Mind and Body Approaches (R01 Clinical Trial Optional)

Issued by

Office of Behavioral and Social Sciences Research (OBSSR)

National Institute on Aging (NIA)

National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)

National Institute of Dental and Craniofacial Research (NIDCR)

National Institute on Drug Abuse (NIDA)

National Institute of Mental Health (NIMH)

National Institute of Nursing Research (NINR)

National Center for Complementary and Integrative Health (NCCIH)

National Cancer Institute (NCI)

Purpose

The Office of Behavioral and Social Sciences Research (OBSSR) and participating ICOs are issuing this Notice to highlight interest in the systematic development of novel health-related behavioral interventions that leverage new, emerging or understudied areas in basic behavioral and social sciences research (bBSSR). To achieve more potent and sustained strategies to promote health-related behavior change, there is a need for intentional and methodical translation of foundational behavioral and social science discoveries into new or improved interventions. This includes research that focuses on use-inspired bBSSR, understanding of mechanisms of action underlying initial and sustained behavior change, and systematic development and testing of health-related behavioral interventions and their components.

Background:

While there have been many important prevention and treatment advances based on behavioral and social science research, it is not uncommon for even the most robust interventions to work only in a subset of those intervened upon and for changes to be difficult to sustain over time. There is a need for intervention development research that bridges basic and applied behavioral science, in which insights from basic research about the mechanisms and moderators of human behavior are used to develop more effective, efficient, and enduring interventions for health-related behavior change.

Research Objectives:

This Notice encourages translational behavioral intervention research, integrated with basic behavioral and social science, aimed at creating, refining, and testing novel interventions focused on the initiation, cessation, or maintenance of behaviors associated with improved health or disease mitigation.

The behavioral, emotional, cognitive, and/or social targets for the intervention/s being developed and tested in response to this NOSI, should be based on insights from basic science about mechanisms that underlie health-related behavior change. Interventions may target the individual (e.g., cognitive or psychological processes), the immediate social environment (e.g., dyadic or family relationships), and/or broader social, organizational or environmental systems (e.g., worksites, schools, healthcare delivery, or neighborhood features).

Outcomes may include clinical indicators or health-related behaviors measured at the individual level or shifts in behavior or health indicators that are measured at an aggregate/population level.

Applicants are encouraged to employ innovative study designs for building, adapting, and optimizing behavioral interventions. Interdisciplinary project teams are also encouraged.

The use of an intervention development framework and/or approach to inform the research plan is encouraged. Examples include, but are not limited to, the Obesity Related Behavioral Intervention Trials (ORBIT) model for behavioral treatment development (https://cancercontrol.cancer.gov/brp/hbrb/translational-research.html; the NIH Stage Model for Behavioral Intervention Development (https://www.nia.nih.gov/research/dbsr/stage-model-behavioral-intervention-development) and the Science of Behavior Change’s experimental medicine approach (https://scienceofbehaviorchange.org/what-is-sobc/)..

Intervention creation and refinement require iterative and systematic testing of intervention features and components. Study timelines should include clear research steps, goals and milestones (go/no-go decision points). It is understood that during the intervention development process, timeline deviations may occur based on study results; for example, findings at one step may require a return to an earlier step to further refine an intervention or better understand the mechanism of action. As such, applicants should include a plan for dealing with unexpected results before proceeding to the next step of the intervention development refinement and testing plan.

IC Specific Application and Submission Information:

Applicants must select the IC and associated FOA to use for submission of an application in response to this NOSI. The selection must align with the IC requirements listed in order to be considered responsive to that FOA. Non-responsive applications will be withdrawn from consideration for this initiative. In addition, applicants using NIH Parent Announcements (listed below) will be assigned to those ICs on this NOSI that have indicated those FOAs are acceptable and based on usual application-IC assignment practices.

  • PA-20-183 -NIH Research Project Grant (Parent R01 Clinical Trial Required)
  • PA-20-184- NIH Research Project Grant (Parent R01 Basic Experimental Studies with Humans Required)
  • PA-20-185 - NIH Research Project Grant (Parent R01 Clinical Trial Not Allowed)
  • PA-20-194 NIH Exploratory/Developmental Research Grant Program (Parent R21 Clinical Trial Required)
  • PA-20-196- NIH Exploratory/Developmental Research Grant Program (Parent R21 Basic Experimental Studies with Humans Required)

All instructions in the SF424 (R&R) Application Guide and the listed funding opportunity announcements must be followed, with the following additions:

  • For funding consideration, applicants must include NOT-OD-20-106 in the Agency Routing Identifier field (box 4B) of the SF424 R&R form. Applications without this information in box 4B will not be considered for this initiative.

Applications nonresponsive to terms of this NOSI will be withdrawn from consideration for this initiative.

National Institute on Drug Abuse (NIDA)

NIDA is interested in research to evaluate behavioral treatments for substance use disorders (SUDs); produce treatments that are implementable and self-sustaining; and develop optimal behavioral strategies to promote medication adherence and other outcomes for SUDs. These efforts include:

  • Research to elucidate purported mechanism of action and targets of behavioral interventions at multiple levels of analysis. This includes determination of underlying biological and/or neurobiological mechanisms (e.g., as measured by imaging methodologies, skin conductance, or other biological/physiological indices) of the interventions associated with the behavioral, cognitive, affective, or social mechanisms of interventions.
  • Research that uses innovative technologies (digital therapeutics, including mobile applications and other platforms, virtual reality, wireless monitoring and biofeedback, imaging tools for biofeedback) to develop, improve and systematically measure behavioral interventions including the use of imaging methods to predict outcomes from behavioral interventions.
  • Research that incorporates genetic/epigenetic methodologies to help understand the variability in outcomes as result of therapeutic interventions.
  • Research that evaluates the use of medications to improve the potency of behavioral interventions.
  • Research on the essential components of a behavioral treatment, adherence or therapist training intervention.
  • Treatment development research aimed at facilitating the implementation of an intervention, testing behavioral interventions within primary care settings
  • Research to promote adherence to pharmacotherapies, such as buprenorphine, methadone, depot naltrexone, lofexidine, naloxone, or HAART, in substance abuse treatment populations.
  • Studies that develop safe and effective psychosocial interventions to improve the outcomes of pharmacotherapies for SUDs including OUD and overdose reversal.
  • Research on tobacco harm reduction strategies such as switching from combustibles to e-cigarettes.

NIDA FOA’s for this NOSI include the following or their subsequent reissued equivalents:

Activity Code

FOA

First Available Due Date

R34

PAR-19-213 - Behavioral & Integrative Treatment Development Program (R34 Clinical Trial Optional)

July 23, 2020

R01

PAR-19-212 - Behavioral & Integrative Treatment Development Program (R01 Clinical Trial Optional)

July 23, 2020

National Institute on Aging (NIA)

NIA is interested in preliminary (Stage I, II, and III) behavioral intervention development for mid-life and older individuals that capitalizes on and integrates basic research to inform the development of efficacious interventions, in accordance with the NIH Stage Model (please see https://www.nia.nih.gov/research/dbsr/stage-model-behavioral-intervention-development. Interventions may be focused on individuals, dyads, families, communities, organizations, or systems. The purpose of the interventions to be developed may be, for example, to promote health and well-being, including emotional/behavioral well-being, (e.g., in caregivers of individuals with dementia), promote behaviors associated with health and well-being (e.g., exercise), establish and maintain high quality and nurturing close relationships, cope with age-related disorders, cope with stress, decrease pain, improve sleep hygiene, promote independence, help older individuals with declining memory improve their memory, prevent disease or disease progression, and prevent cognitive decline. NIA is also interested in supporting Alzheimer’s disease Alzheimer’s disease-related dementias (AD/ADRD)-focused research on interventions for care providers and also preliminary behavioral interventions focused at increasing long-term adherence to lifestyle interventions, such as diet and physical activity, that might delay the onset and progression of AD/ADRD. Applicants are also encouraged to consider the ultimate scalability of interventions and may conduct preliminary research to adapt/modify interventions to streamline interventions, optimize the ability to deliver interventions with fidelity and/or improve real-world ease of implementation.

NIA’s FOA’s for this NOSI include the following or their subsequent reissued equivalents:

Activity Code

FOA

First Available Due Date

R01

PA-18-849 - Prevention Research in Mid-Life Adults (R01 Clinical Trial Optional)

October 5, 2020

R21

PA-18-850 - Prevention Research in Mid-Life Adults (R21 Clinical Trial Optional)

October 16, 2020

R01

PA-18-722 - Improving Patient Adherence to Treatment and Prevention Regimens to Promote Health (R01 Clinical Trial Optional)

October 5, 2020

R21

PA-18-723 - Improving Patient Adherence to Treatment and Prevention Regimens to Promote Health (R21 Clinical Trial Optional)

October 16, 2020

R01

PAR-18-581 - Emotional Function in Normal Aging and/or MCI and AD/ADRD (R01 - Clinical Trial Optional)

July 8, 2020

R21

PAR-18-538 - Basic and Translation Research on Decision Making in Aging and Alzheimer's Disease (R21 - Clinical Trial Optional)

June 22, 2020

R01

PAR-18-877 - Early Stage Clinical Trials for the Spectrum of Alzheimer's Disease and Age-related Cognitive Decline (R01 Clinical Trial Optional)

October 5, 2020

R21/R33

PAR-20-070 - Research Infrastructure Development for Interdisciplinary Aging Studies (R21/R33 - Clinical Trial Optional)

October 16, 2020

R01

PAR-19-070 - Research on Current Topics in Alzheimer's Disease and Its Related Dementias (R01 Clinical Trial Optional)

July 9, 2020

R01

PA-20-184- NIH Research Project Grant (Parent R01 Basic Experimental Studies with Humans Required)

October 5, 2020

R01

- PA-20-183 - Research Project Grant (Parent R01 Clinical Trial Required)

October 5, 2020

R21

PA-20-196- NIH Exploratory/Developmental Research Grant Program (Parent R21 Basic Experimental Studies with Humans Required)

October 16, 2020

R21

PA-20-194 NIH Exploratory/Developmental Research Grant Program (Parent R21 Clinical Trial Required)

October 16, 2020

National Cancer Institute (NCI)

The National Cancer Institute (NCI) seeks to support and catalyze research on the discovery, development, testing, and implementation of effective strategies to promote healthy lifestyle behaviors for cancer prevention and control. Early-phase (basic-to-clinical) behavioral translation studies (e.g., Phase I or Phase II studies, as defined by the ORBIT model for behavioral treatment development (see http://www.ncbi.nlm.nih.gov/pubmed/25642841) are of particular interest, including research that elucidates the causal factors related to cancer risk behaviors, identifies potential targets for intervention, and/or involves the design and optimization of interventions to promote and sustain healthy behaviors related to cancer prevention and control.

Research in response to this Notice can involve any aspect of the cancer control continuum (e.g., prevention, detection/diagnosis, treatment, survivorship). Cancer-related behavioral risk factors of interest to NCI include tobacco use; diet; energy balance and obesity; physical activity and sedentary behavior; sun safety/UV-protective behaviors and tanning; alcohol use; sleep and circadian function; adherence to cancer-related medical and behavioral regimens; cancer screening; vaccinations to prevent cervical cancer (HPV vaccination); and avoidance of environmental carcinogens (e.g., radon).

The following are of special interest:

  • Use of the ORBIT model for behavioral treatment development (see http://www.ncbi.nlm.nih.gov/pubmed/25642841) to guide the aims, study designs and methods proposed, with a focus on Phase I and/or Phase II of the ORBIT model;
  • New and innovative research designs, alone or in combination, including (but not limited to) mixed-methods, qualitative and user-centered methods; single-case and N-of-1 designs; dose-finding methods; proof-of-concept studies; full and fractional factorial (e.g., as used in Multiphase Optimization Strategy [MOST]) designs; adaptive interventions (e.g., using SMART, JITAI and microrandomized trials);
  • Interventions, including those involving natural experiments, targeting the built, sociocultural, communication, and policy environments that affect cancer risk and behavioral risk factors;
  • New and existing data collection systems (e.g., smart phone-based, sensor data, electronic health records) and integrated datasets;
  • Multi-level interventions, including combinations of at least two levels of analysis (e.g., community and clinical settings) that are hypothesized to produce both independent and joint effects and that address complex behaviors;
  • Multi-behavior interventions (e.g., targeting bundles or clusters of behavioral risk factors) including combinations of at least two behaviors, with innovations in the combination of behaviors, the intervention approach, or both;
  • Developing and preliminary testing of interventions prior to, during or following cancer treatment that aim to improve symptom management, cancer risk, recurrence, and quality of life;
  • Using systems-level methods (e.g., agent-based modeling, system dynamics) to identify drivers of cancer-related risk behaviors and points of entry for interventions.

NCI FOA’s for this NOSI include the following or their subsequent reissued equivalents:

Activity Code

FOA

First Available Due Date

R01

PAR-18-069 - Modular R01s in Cancer Control and Population Sciences (R01 Clinical Trial Optional)

November 6, 2020

R21

PAR-19-309 - Stimulating Innovations in Behavioral Intervention Research for Cancer Prevention and Control (R21 Clinical Trial Optional)

October 16, 2020

R01

PAR-18-559 - Cancer Prevention and Control Clinical Trials Grant Program (R01 Clinical Trial Required)

October 5, 2020

R21/R33

PAR-18-307 - Developing Interventions for Health-Enhancing Physical Activity (R21/R33 - Clinical Trial Optional)

October 16, 2020

R21

PAR-18-892 - Physical Activity and Weight Control Interventions Among Cancer Survivors: Effects on Biomarkers of Prognosis and Survival (R21 Clinical Trial Optional)

October 16, 2020

R01

PAR-18-893 - Physical Activity and Weight Control Interventions Among Cancer Survivors: Effects on Biomarkers of Prognosis and Survival (R01 Clinical Trial Optional)

October 5, 2020

National Institute of Dental and Craniofacial Research (NIDCR):

NIDCR prioritizes behavioral and social science intervention research that includes rigorous empirical tests of putative mechanisms of action, across the translational continuum. As such, high priority projects will draw on knowledge from basic behavioral and social science to develop behavioral interventions and accompanying mechanistic hypotheses that address current challenges or opportunities related to dental, oral, and craniofacial (DOC) health. NIDCR supports a broad range of DOC intervention research projects, for participants of any age or developmental stage; for any DOC condition with public health significance (e.g., dental caries, periodontal disease, craniofacial anomalies, oral cancers, salivary gland dysfunctions, oral mucosal diseases, orofacial pain); for a range of outcomes (e.g., direct intervention with patients to improve DOC outcomes, intervention with practitioners to improve DOC care, intervention on health systems to improve continuity of care); for stakeholders from different sectors (e.g., patients, families, social networks and communities, practitioners, care-delivery systems, professional organizations, policy-makers); and for DOC intervention research at all stages, from early intervention development (e.g., Stage I) through implementation and health services research (Stages IV/V).

NIDCR FOA’s for this NOSI include the following or their subsequent reissued equivalents:

Activity Code

FOA

First Available Due Date

UG3/UH3

PAR-18-656 - NIDCR Behavioral and Social Intervention Clinical Trial Planning and Implementation Cooperative Agreement (UG3/UH3 Clinical Trial Required)

October 8, 2020

R01

PA-19-091 - NIH Research Project Grant (Parent R01 Basic Experimental Studies with Humans Required)

October 5, 2020

R21

PA-19-092 - NIH Exploratory/Developmental Research Grant Program (Parent R21 Basic Experimental Studies with Humans Required)

October 16, 2020

R01

PA-18-932 - Increasing Uptake of Evidence-Based Screening in Diverse Adult Populations (R01 Clinical Trial Optional)

October 5, 2020

R01

PAR-18-612 - Electronic Nicotine Delivery Systems (ENDS): Population, Clinical and Applied Prevention Research (R01 Clinical Trial Optional)

June 27, 2020

R21

PAR-18-611 - Electronic Nicotine Delivery Systems (ENDS): Population, Clinical and Applied Prevention Research (R21 Clinical Trial Optional)

June 27, 2020

R01

PA-18-729 - Research on the Health of Transgender and Gender Nonconforming Populations (R01 Clinical Trial Optional)

October 5, 2020

R21

PA-18-728 - Research on the Health of Transgender and Gender Nonconforming Populations (R21 Clinical Trial Optional)

October 16, 2020

R01

PAR-19-274 - Dissemination and Implementation Research in Health (R01 Clinical Trial Optional)

October 5, 2020

National Institute of Nursing Research (NINR)

The mission of the National Institute of Nursing Research (NINR) is to promote and improve the health of individuals, families, and communities. In the context of this NOSI, NINR is interested in research aimed at generating evidence of sustained behavior change in relation to self-management of chronic conditions, symptom management, and/or health promotion and disease prevention (to include HIV/AIDS). In addition, NINR is interested in behavioral interventions in the context of palliative and end-of-life care that incorporate basic behavioral and social sciences to address clinical indicators or health-related behaviors measured at the individual and/or family level. Interventions with social and behavioral theoretical underpinnings are encouraged. Only non-pharmacologic strategies are acceptable. NINR outcomes of interest include, but are not limited to, self-efficacy, symptom burden, disease/condition predictor variables, behavioral/emotional or psychosocial determinants of behavioral change, and characteristics of patient/provider relationships that give rise to sustained behavior change.

NINR FOA’s for this NOSI include the following or their subsequent reissued equivalents:

Activity Code

FOA

First Available Due Date

R01

PA-19-056 - NIH Research Project Grant (Parent R01 Clinical Trial Not Allowed)

October 5, 2020

R01

PA-19-055 - Research Project Grant (Parent R01 Clinical Trial Required)

October 5, 2020

R01

PAR-17-491 - Implementing the Most Successful Interventions to Improve HIV/AIDS Outcomes in U.S. Communities (R01 Clinical Trial Optional)

October 5, 2020

R01

PA-18-849 - Prevention Research in Mid-Life Adults (R01 Clinical Trial Optional)

October 5, 2020

R01

PA-18-945 - Applying a Biopsychosocial Perspective to Self-Management of Chronic Pain (R01 Clinical Trial Optional)

October 5, 2020

R01

PA-18-944 - Biobehavioral Basis of Chronic Pain (R01 Clinical Trial Optional)

October 5, 2020

R01

PAR-19-045 - End-of-Life and Palliative Care Approaches to Advanced Signs and Symptoms (R01 Clinical Trial Optional)

October 5, 2020

R21

PAR-19-044 - End-of-Life and Palliative Care Approaches to Advanced Signs and Symptoms (R21 Clinical Trial Optional)

October16, 2020

R01

PAR-19-057 - Strategies to Provide Culturally Tailored Palliative and End-of-Life Care for Seriously Ill American Indian and Alaska Native Individuals (R01 Clinical Trial Optional)

October 5, 2020

R21

PAR-19-058 - Strategies to Provide Culturally Tailored Palliative and End-of-Life Care for Seriously Ill American Indian and Alaska Native Individuals (R21 Clinical Trial Optional)

October 16, 2020

R01

PAR-19-136 - End-of-Life and Palliative Needs of Adolescents and Young Adults (AYA) with Serious Illnesses (R01 Clinical Trial Optional)

October 5, 2020

R21

PAR-19-153 - End-of-Life and Palliative Needs of Adolescents and Young Adults (AYA) with Serious Illnesses (R21 Clinical Trial Optional)

October 16, 2020

R01

PAR-19-321- Palliative Care in Home and Community Settings (R01 Clinical Trial Optional)

October 5, 2020

R21

PAR-19-320 - Palliative Care in Home and Community Settings (R21 Clinical Trial Optional)

October16, 2020

National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)

The NIAMS is interested in behavioral research focused on musculoskeletal, rheumatic and skin diseases and conditions:

  • Incorporating findings from behavioral research to develop patient education strategies to promote adoption of healthy behaviors.
  • Using mobile health technologies (e.g., smart phones) and web-based technologies to facilitate research on the role of behavioral factors in diseases and conditions within NIAMS core mission.
  • Studying the interaction of biological influences with social and/or behavioral factors as they relate to onset, progression, and outcomes of diseases and conditions within NIAMS core mission.
  • Exploring behavioral factors that influence patient interactions with providers and how this experience affects treatment response and long-term outcomes.
  • Using social, commercial, economic, gender, ethnic, and cognitive data (“Big Data”) to understand correlations between behavior and diseases and conditions within NIAMS core mission.
  • Developing animal models to elucidate behavioral mechanisms in diseases and conditions within NIAMS core mission.
  • Studying mechanisms by which stress affects musculoskeletal, rheumatic and skin diseases and conditions progression and how stress management affects disease outcomes and treatment response.
  • Identifying a set of behavioral that make an individual susceptible to chronic pain, cause the transition from acute to chronic pain, or influence the transition from pediatric to adult pain.
  • Developing behavioral interventions to improve both pain and related co-morbidities such as fatigue, depression, and sleep disturbance.
  • Developing nonpharmacologic interventions such as behavioral or biopsychosocial approaches to improve function and alleviate pain.
  • Developing new therapies to prevent fractures associated with osteoporosis and related conditions, including behavioral or biopsychosocial approaches, such as exercise, nutrition intervention, biofeedback.
  • Conducting trials that test behavioral interventions that advance muscle-disease treatments.
  • Conducting trials with behavioral interventions that address health services outcomes and daily living issues in people with muscle diseases.
  • Exploring interventions, including behavioral modification and protective strategies, to prevent skin exposure to environmental harm that causes disease and accelerates skin aging.
  • Investigating management of chronic symptoms, such as itching and pain, as well as ways to minimize effects of these symptoms on stress level, sleep, and overall quality of life.

NIAMS FOA’s for this NOSI include the following or their subsequent reissued equivalents:

Activity Code

FOA

First Available Due Date

R21

PA-18-943 - Biobehavioral Basis of Chronic Pain (R21 Clinical Trial Optional)

October 16, 2020

R01

PA-18-944 - Biobehavioral Basis of Chronic Pain (R01 Clinical Trial Optional)

October 5, 2020

R01

PAR-19-274 - Dissemination and Implementation Research in Health (R01 Clinical Trial Optional)

October 5, 2020

R21

PAR-19-275 - Dissemination and Implementation Research in Health (R21 Clinical Trial Optional)

October 16, 2020

R21

PAR-18-595 - Exploratory Clinical Trial Grants in Arthritis and Musculoskeletal and Skin Diseases (R21 Clinical Trial Required)

October 2, 2020

Admin Supp

PA-18-592 - Research Supplements to Promote Re-Entry into Biomedical and Behavioral Research Careers (Admin Supp - Clinical Trial Not Allowed)

See Table of IC-Specific Information, Requirements and Staff Contacts for more details.

National Institute of Mental Health (NIMH):

NIMH supports the efficient pilot testing of novel psychosocial therapeutic and preventive interventions for mental disorders in adults and children, as well as pilot testing of interventions to advance HIV prevention and treatment. Applicants are strongly encouraged to consult with NIMH staff when developing plans for an application. NIMH uses a set of institute-specific FOAs to support development and testing of interventions. These FOAs require a mechanism-based, experimental therapeutics approach, whereby empirically-supported proximal intervention targets are specified, and the study is explicitly designed to examine whether the intervention leads to changes in the hypothesized targets, and whether these intervention-induced changes in the targets lead to changes in the clinical outcome(s) of interest. A target may be a disease mechanism, a factor related to a disease mechanism, or a factor that confers significant risk. Targets can range from molecular processes, to synaptic- and circuit-level regions or networks, to neural systems and cognitive or emotional processes, to provider behavior, decision-making or organizational policies or behaviors. Appropriate targets will depend on the intervention modality and the conceptual framework underlying hypotheses about its mechanism of action. For early-stage development of novel interventions consistent with this NOSI, NIMH uses a selected set of RFAs (noted below) to support the development of psychosocial (e.g., psychotherapeutic, behavioral) interventions for prevention and treatment of mental disorders among youth, adults, and older adults, where the goal is translation of basic findings from behavioral/social science into novel intervention targets and/or strategies. Applicants are strongly encouraged to consult the NIMH resources and staff contacts listed on the NIMH support for clinical trials research webpage early in the application development process to best match current NIMH priorities and relevant clinical trials FOAs.

NIMH FOA’s for this NOSI include the following or their subsequent reissued equivalents:

Activity Code

FOA

First Available Due Date

R61/R33

RFA-MH-18-704 - Development of Psychosocial Therapeutic and Preventive Interventions for Mental Disorders (R61/R33 - Clinical Trial Required)

October 15, 2020

R33

RFA-MH-18-705- Development of Psychosocial Therapeutic and Preventive Interventions for Mental Disorders (R33 - Clinical Trial Required)

October 15, 2020

R34

RFA-MH-18-706 - Pilot Effectiveness Trials for Treatment, Preventive and Services Interventions (R34 - Clinical Trial Required)

October 15, 2020

R34

PA-20-141 - Formative and Pilot Intervention Research for Prevention and Treatment of HIV/AIDS (R34 - Clinical Trial Optional)

September 7, 2020

National Center for Complementary and Integrative Health (NCCIH):

NCCIH is committed to the rigorous investigation of promising mind and body behavioral interventions. These mind and body approaches are widely used by the public, and they are increasingly recognized to provide a non-pharmacological approach to symptom management (e.g., chronic pain, mild depression, anxiety, etc.). These approaches can be utilized by individuals to help prevent, treat, or self-manage various conditions (e.g., chronic pain, headache, anxiety, promote wellness), as well as being complementary to treatment offered by conventional health care. Mind and body interventions include various mind-based approaches (e.g., mindfulness, hypnosis, guided imagery), body-based approaches (e.g., spinal manipulation, massage, mobilization, acupuncture), meditative movement approaches (e.g., yoga, tai chi, qi-gong), music and art therapy approaches, or a combination of these approaches (e.g., meditation and yoga, or mindfulness-based stress reduction MBSR).

NCCIH is interested in research to develop and test mind and body behavioral interventions for the following high priority topic areas: symptom management - particularly for chronic pain syndromes; reduction of prescription drug (opioid) use or abuse in patients with chronic pain; enhancement of medication adherence; treatment or prevention of post-traumatic stress (disorder), traumatic brain injury, sleep disorders or disturbances, anxiety, depression, obesity, and smoking; promotion of psychological resilience or wellbeing; and promotion of healthy eating and physical activity. For more details on NCCIH’s approach to funding clinical trials, including a description of our available FOA’s, please see https://nccih.nih.gov/grants/funding/clinicaltrials.

NCCIH FOA’s for this NOSI include the following or their subsequent reissued equivalents:

Activity Code

FOA

First Available Due Date

R21

PA-18-322 - Fundamental Science Research on Mind and Body Approaches (R21 Clinical Trial Optional)

October 16, 2020

R01

PA-18-323 - Fundamental Science Research on Mind and Body Approaches (R01 Clinical Trial Optional)

October 5, 2020

Application and Submission Information

This notice applies to due dates on or after June 22, 2020 and subsequent receipt dates through September 26, 2022.

All instructions in the SF424 (R&R) Application Guide and the funding opportunity announcement used for submission must be followed, with the following additions:

  • For funding consideration, applicants must include “NOT-OD-20-106” (without quotation marks) in the Agency Routing Identifier field (box 4B) of the SF424 R&R form. Applications without this information in box 4B will not be considered for this initiative.
Applications nonresponsive to terms of this NOSI will be withdrawn from consideration for this initiative.

Inquiries

Please direct all inquiries to the contacts in Section VII of the listed funding opportunity announcements with the following additions/substitutions:

Scientific Contacts:

Will M. Aklin, Ph.D.
National Institute on Drug Abuse (NIDA)
Telephone: 301-827-5909
Email: aklinwm@nida.nih.gov

Lisa Onken, Ph.D.
National Institute on Aging (NIA)
Telephone: 301-496-3136
Email: lisa.onken@nih.gov

Susan M. Czajkowski, PhD
National Cancer Institute (NCI)
240-276-5871
Email: Susan.Czajkowski@nih.gov

Elise Rice, PhD

National Institute of Dental and Craniofacial Research (NIDCR)

Telephone: 301-594-4814

Email: Elise.Rice@nih.gov

Karen A. Kehl, PhD, RN, FPCN

National Institute of Nursing Research (NINR)

Telephone: 301-594-8010

Email: karen.kehl@nih.gov

Ricardo R. Cibotti, Ph.D.

National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)

Telephone: 301-451-5888

Email: cibottirr@mail.nih.gov

Alexander Talkovsky, Ph.D.

National Institute of Mental Health (NIMH)

Telephone: 301-827-7614

Email: alexander.talkovsky@nih.gov

Lanay M. Mudd, Ph.D.

National Center for Complementary and Integrative Health (NCCIH)

Telephone: 301-594-9346

Email: lanay.mudd@nih.gov

Peer Review Contacts:

Examine your eRA Commons account for review assignment and contact information (information appears two weeks after the submission due date).

Grants Management Contacts:

Ericka Wells
National Institute on Drug Abuse (NIDA)
Telephone: 301-443-6710
Email: wellse2@nida.nih.gov

Nia Pree

National Institute on Aging (NIA)

Telephone: 301-827-6374

Email: Nia.Pree@nih.gov

Crystal Wolfrey
National Cancer Institute (NCI)
Telephone: 240-276-6277
Email: wolfreyc@mail.nih.gov:

Diana Rutberg, MBA
National Institute or Dental and Craniofacial Research (NIDCR)
Telephone: 301-594-4798
Email: rutbergd@mail.nih.gov

Ron Wertz

National Institute of Nursing Research (NINR)

Telephone: 301-594-2807

Email: wertzr@mail.nih.gov

Sarisa Kowl

National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)

Telephone: 301-827-2258

Email: sarisa.kowl@nih.gov

Rita Sisco

National Institute of Mental Health (NIMH)

Telephone: 301-443-2805

Email: siscor@mail.nih.gov

Shelley Carow
National Center for Complementary and Integrative Health (NCCIH)
Telephone: 301-594-3788
Email: CarowS@mail.nih.gov


Weekly TOC for this Announcement
NIH Funding Opportunities and Notices